1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
--------------
Date of Report (Date of earliest event reported): November 15, 1999
GELTEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-26872 04-3136767
- --------------- ------------ -------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
153 SECOND AVENUE, WALTHAM, MASSACHUSETTS 02451
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 781-290-5888
------------
Nine Fourth Avenue, Waltham, Massachusetts 02451
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Page 1 of 4 pages
2
ITEM 5. OTHER EVENTS.
On November 15, 1999, the Registrant publicly disseminated a press release
announcing that the Registrant had entered into a binding Letter of Intent with
Sankyo Pharma, Inc. to grant Sankyo Pharma, Inc. exclusive marketing rights in
the United States for Cholestagel(R) (colesevelam hydrochloride) for the
treatment of hypercholesterolemia, characterized by undesirably high blood
cholesterol levels. Under the Letter of Intent, Sankyo has also agreed to
purchase an option to global rights to GelTex's second generation
cholesterol-lowering product. The information contained in the press release is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated November 15, 1999.
Page 2 of 4 pages
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GelTex Pharmaceuticals, Inc.
----------------------------
(Registrant)
Date: November 15, 1999 /s/ Mark Skaletsky
-------------------------------
Mark Skaletsky
President and CEO
Page 3 of 4 pages
4
EXHIBIT INDEX
Exhibit Sequential
Number Description Page Number
- ------- ----------- -----------
99.1 The Registrant's Press Release 4
dated.
Page 4 of 4 pages